Pharma News
Mylan will not be acquiring Perrigo
Generics company Mylan has failed in its lengthy multi-billion dollar hostile bid to acquire competing generics company Perrigo.
Pfizer cuts some biosimilars after Hospira deal
After completing its US$17 billion acquisition of Hospira, Pfizer is cutting some of its biosimilar collaborations with South Korean drugmaker Celltrion.
Merck Millipore to collaborate with Turkish firm on biosimilars
The Life Science division of Merck, Merck Millipore and Turkish biosimilars start-up Turgut Ilaç are to collaborate on biosimilars.
Teva acquires Mexican drugmaker Rimsa
Israeli generics giant Teva Pharmaceutical Industries (Teva) is expanding its presence in emerging markets with its acquisition of Mexico-based Representaciones e Investigaciones Medicas SA de CV (Rimsa), a specialty drugmaker with a portfolio of products and patents across Latin America.
Mylan goes after Perrigo
US generics manufacturer Mylan announced on 14 September 2015 that it had officially commenced its formal offer to acquire all outstanding ordinary shares of rival Ireland-based generics maker Perrigo Company (Perrigo).
Epirus expands biosimilars pipeline with Bioceros acquisition
US-based Epirus Biopharmaceuticals (Epirus) announced on 9 September 2015 that it has acquired Netherlands-based biopharmaceutical company Bioceros Holding (Bioceros).
UCB sells generics unit to Lannett
Belgium-based biopharmaceutical company UCB announced on 2 September 2015 that it would sell its US specialty generics business, Kremers Urban, to US generics company Lannett for US$1.23 billion in cash plus contingent payments.
US FTC clears Pfizer’s purchase of Hospira
Pharma giant Pfizer announced on 24 August 2015 that the US Federal Trade Commission (FTC) terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of US-based injectable generics specialist and biosimilars maker Hospira.
ANI Pharma and IDT Australia collaborate on US generics
US-based brand-name and generic drugmaker ANI Pharmaceuticals (ANI) announced on 12 August 2015 that it had entered into a collaboration with generics company IDT Australia (IDT) to commercialize up to 18 previously marketed US generics.
Mergers between Watson/Actavis and ANI Pharma/BioSante
Mergers are once again on the agenda as companies strive to meet the constant demands of governments to cut costs and yet still make a profit.
